Molecular Neurodegeneration (Nov 2017)

YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias

  • Franc Llorens,
  • Katrin Thüne,
  • Waqas Tahir,
  • Eirini Kanata,
  • Daniela Diaz-Lucena,
  • Konstantinos Xanthopoulos,
  • Eleni Kovatsi,
  • Catharina Pleschka,
  • Paula Garcia-Esparcia,
  • Matthias Schmitz,
  • Duru Ozbay,
  • Susana Correia,
  • Ângela Correia,
  • Ira Milosevic,
  • Olivier Andréoletti,
  • Natalia Fernández-Borges,
  • Ina M. Vorberg,
  • Markus Glatzel,
  • Theodoros Sklaviadis,
  • Juan Maria Torres,
  • Susanne Krasemann,
  • Raquel Sánchez-Valle,
  • Isidro Ferrer,
  • Inga Zerr

DOI
https://doi.org/10.1186/s13024-017-0226-4
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 21

Abstract

Read online

Abstract Background YKL-40 (also known as Chitinase 3-like 1) is a glycoprotein produced by inflammatory, cancer and stem cells. Its physiological role is not completely understood but YKL-40 is elevated in the brain and cerebrospinal fluid (CSF) in several neurological and neurodegenerative diseases associated with inflammatory processes. Yet the precise characterization of YKL-40 in dementia cases is missing. Methods In the present study, we comparatively analysed YKL-40 levels in the brain and CSF samples from neurodegenerative dementias of different aetiologies characterized by the presence of cortical pathology and disease-specific neuroinflammatory signatures. Results YKL-40 was normally expressed in fibrillar astrocytes in the white matter. Additionally YKL-40 was highly and widely expressed in reactive protoplasmic cortical and perivascular astrocytes, and fibrillar astrocytes in sporadic Creutzfeldt-Jakob disease (sCJD). Elevated YKL-40 levels were also detected in Alzheimer’s disease (AD) but not in dementia with Lewy bodies (DLB). In AD, YKL-40-positive astrocytes were commonly found in clusters, often around β-amyloid plaques, and surrounding vessels with β-amyloid angiopathy; they were also distributed randomly in the cerebral cortex and white matter. YKL-40 overexpression appeared as a pre-clinical event as demonstrated in experimental models of prion diseases and AD pathology. CSF YKL-40 levels were measured in a cohort of 288 individuals, including neurological controls (NC) and patients diagnosed with different types of dementia. Compared to NC, increased YKL-40 levels were detected in sCJD (p 0.05, AUC = 0.71) or in DLB/Parkinson’s disease dementia (PDD) (p > 0.05, AUC = 0.70). Further, two independent patient cohorts were used to validate the increased CSF YKL-40 levels in sCJD. Additionally, increased YKL-40 levels were found in genetic prion diseases associated with the PRNP-D178N (Fatal Familial Insomnia) and PRNP-E200K mutations. Conclusions Our results unequivocally demonstrate that in neurodegenerative dementias, YKL-40 is a disease-specific marker of neuroinflammation showing its highest levels in prion diseases. Therefore, YKL-40 quantification might have a potential for application in the evaluation of therapeutic intervention in dementias with a neuroinflammatory component.

Keywords